GlassScriptPhysician profile
Adelor Zamora
NPI 1790080133
$1,300.77
in general payments reported to CMS, 2019-2025
14 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $175 · 2021: $144 · 2022: $203 · 2023: $163 · 2024: $14.43 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $678.45 | 2019-2025 | Collagenase Santyl, Regranex |
| Melinta Therapeutics, LLC | $173.85 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Organogenesis INC. | $79.24 | 2019 | |
| Paratek Pharmaceuticals, INC. | $75.12 | 2022-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $71.33 | 2023-2025 | Pifeltro, Dificid, Delstrigo |
| Insmed, INC. | $52.84 | 2025 | Arikayce |
| Convatec INC. | $31.52 | 2020-2023 | |
| Hydrofera LLC | $25.63 | 2023 | Hydrofera Blue |
| Shionogi INC | $23.03 | 2023 | Fetroja |
| Grifols USA, LLC | $19.53 | 2025 | Gamunex-C |
| Misonix INC | $19.53 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $19.25 | 2021 | |
| Viiv Healthcare Company | $19.08 | 2023 | Dovato |
| Integra Lifesciences Corporation | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelor Zamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.